International Biotechnology (LON:IBT) Stock Price Crosses Above 200 Day Moving Average – Should You Sell?

International Biotechnology (LON:IBTGet Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 945.04 and traded as high as GBX 970. International Biotechnology shares last traded at GBX 966, with a volume of 39,518 shares traded.

International Biotechnology Stock Performance

The company has a debt-to-equity ratio of 9.43, a quick ratio of 0.32 and a current ratio of 0.11. The stock has a market cap of £308.10 million, a P/E ratio of -294.22 and a beta of 0.32. The firm’s 50 day moving average is GBX 961.08 and its 200 day moving average is GBX 945.04.

International Biotechnology (LON:IBTGet Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported GBX (4.83) EPS for the quarter. The firm had revenue of GBX 24 million for the quarter. International Biotechnology had a return on equity of 27.35% and a net margin of 82.27%. Analysts anticipate that International Biotechnology will post 0.9435943 EPS for the current year.

About International Biotechnology

(Get Free Report)

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology. Investments may also be made in related sectors such as medical devices and healthcare services.

Further Reading

Receive News & Ratings for International Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.